PTC Therapeutics is evolving from a legacy rare disease company to a growth-focused business, driven by the successful launch of Sephience. The new product's rapid uptake is compensating for declines in its Duchenne muscular dystrophy (DMD) franchise, with Q1 2026 revenues up 47% year-over-year and strong patient onboarding. Its partnership with Novartis on votoplam for Huntington's disease offers promising late-stage potential. With $1.9 billion in cash, PTC has strategic flexibility and reduced near-term dilution risk. Despite these strengths, the company trades at a significant valuation discount compared to peers, presenting a potential investment opportunity.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
